AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02782741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alglucosidase alfa (GZ419829)
Description: Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous
Study NCT01997008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Positive Affect Skills Training
Study NCT06280898 — intervention group
Intervention type: PROCEDURE
Intervention: Remote ischemic conditioning
Description: Remote ischemic condition
Study NCT00325819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
Study NCT02037477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium
Description: Rabeprazole sodium tablets
Study NCT00325819 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
Study NCT03615313 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1 antibody expressing mesoCAR-T cells
Description: Patients with mesothelin positive cancer will be infused the PD-1 antibody expressing mesoCAR-T cells. The modified mesoCAR-T cells can specifically kill mesothelin positive cancer cells and secrete PD-1 antibody, which could enhance the cytotoxicity of mesoCAR-T cells and activate the tumor infiltrating lymphocytes.
Study NCT03227718 — intervention group
Intervention type: BEHAVIORAL
Intervention: VOR and coordination measurements
Description: measurement of VOR and VOR suppression in addition to hand-eye coordination tasks
Study NCT01775007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brillouin Ocular Analyser
Description: Measurement of the local viscoelastic properties (Brillouin Shift) of the Anterior Eye Segment.
Study NCT03327324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Using Mentored Behavioral and Environmental Restructuring
Description: SLUMBER is a non-pharmacological intervention program, delivered by providing mentoring to facility staff who work directly with residents. SLUMBER focuses on detecting sleep-disruptive factors including: nighttime noise and patient behaviors associated with poor sleep quality; disruptions caused by nighttime caregiving; daytime inactivity; and limited light exposure. In this model, staff-delivered interventions to improve these factors improve sleep quality thereby creating opportunities to test the impact of improving sleep quality (measured by actigraphy) on mood (depression and anxiety), pain, cognitive function, functional ability, and observed activity levels.
Study NCT03656627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be given as an IV infusion every two weeks, in an outpatient setting. One cycle is a 28-day period, with Nivolumab given on days 1 and 15 of a 28-day cycle.~For each cohort, all patients will be dosed at 240 mg IV. There will be no dose de-escalation or escalation from this dose level.
Study NCT04009265 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: adjuvant treatment
Description: adjuvant treatments include chemotherapy or chemoradiotherapy
Study NCT01791595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3965
Description: Day -7: single dose of 5 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 5 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor.
Study NCT01791595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3965
Description: Day -7: single dose of 10 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 10 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor.
Study NCT01791595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3965
Description: Day -7: single dose of 20 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 20 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor.
Study NCT01791595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3965
Description: Day -7: single dose of 30 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 30 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor.
Study NCT01791595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3965
Description: Day -7: single dose of 30 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 15 mg AZD3965 BD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor.
Study NCT01791595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3965
Description: Day -7: single dose of 20 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 10 mg AZD3965 BD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor.
Study NCT01791595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3965
Description: Day -7: single dose of 20 mg AZD3965 orally prior to start of continuous treatment (first 3 trial participants in the Expansion Cohort only; subsequent patients started treatment at Cycle 1, Day 1).~Cycle 1, Day 1: commenced dosing of 10 mg AZD3965 BD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor.
Study NCT00218231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 mg/day bupropion-sr
Description: 300 mg/day for 1 week
Study NCT00218231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0 mg/day bupropion-sr
Description: 0 mg/day bupropion-sr
Study NCT01134224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: 0.4 U/kg body weight injected subcutaneously (under the skin) once
Study NCT01134224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: 0.6 U/kg body weight injected subcutaneously (under the skin) once
Study NCT01134224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: 0.8 U/kg body weight injected subcutaneously (under the skin) once
Study NCT01134224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: 0.4 U/kg body weight injected subcutaneously (under the skin) once
Study NCT01134224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: 0.6 U/kg body weight injected subcutaneously (under the skin) once
Study NCT01134224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: 0.8 U/kg body weight injected subcutaneously (under the skin) once
Study NCT04264377 — intervention group
Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: Bronchoscopy for retrieval of airway cells
Study NCT04394377 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed
Description: Routine full anticoagulation strategy
Study NCT04394377 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Group 2: control group with enoxaparin 40mg/d
Description: Usual standard of care and currently have no indication of full anticoagulation.
Study NCT00378664 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lumbar to sacral ventral nerve re-routing procedure
Description: surgical nerve re-routing procedure
Study NCT02290808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Theory-based group
Description: Workbooks and mini-counselling sessions will be provided to participants in this group.
Study NCT01049451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTH
Description: Subjects assigned to the ACTH arm will receive ACTH (Acthar gel) as intramuscular (IM) injections once a day for 3 consecutive days on a monthly basis, for 12 consecutive months. The dosage of ACTH will be 80 units per injection, for a total of 240 units over the three day period.
Study NCT01049451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Subjects assigned to the MP arm will receive intravenous (IV) infusions of 1 gram of MP once a month for 12 months
Study NCT05190783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formocresol
Description: mixture of formalin, cresol and glycerine used for fixation of pulp tissues
Study NCT05190783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formocresol
Description: mixture of formalin, cresol and glycerine used for fixation of pulp tissues
Study NCT05190783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTA
Description: material used for pulp regeneration, direct and indirect pulp capping
Study NCT05190783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TheraCal
Description: light cured resin modified calcium silicate filled liner designed for use in direct and indirect pulp capping
Study NCT05190783 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulpotomy
Description: removal of the carious tooth structure and unroofing of the pulp chamber with a round carbide bur with high speed and water spray. The coronal pulp tissue will be then removed using a #4 carbide bur with slow speed and sharp spoon excavator.
Study NCT05190783 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulpotomy
Description: removal of the carious tooth structure and unroofing of the pulp chamber with a round carbide bur with high speed and water spray. The coronal pulp tissue will be then removed using a #4 carbide bur with slow speed and sharp spoon excavator.
Study NCT05190783 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: partial pulpotomy
Description: complete removal of caries till exposure occurs. The exposed surface of the pulp will be gently removed using a sterile round diamond bur and a high-speed, water-cooled handpiece with light hand pressure. The removal of the pulp did not exceed approximately two mm.
Study NCT02686177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Study NCT02686177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin or sulfonylurea
Study NCT00218114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium
Description: Participants are titrated over 2 weeks, as tolerated to 10 mgs / pound, and blood levels are checked to determine that the blood level is between 50-110 micrograms / ml.
Study NCT00218114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be on matching placebo.
Study NCT00894205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: strengthening exercise program
Description: A low intensity strengthening exercise program based on the Tufts University Strong Bones program. Utilizes small free weights and chair exercises. Participants attend community based class 2-3x/wk for 4 wks.
Study NCT03224793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB059
Description: Administered as specified in the treatment arm
Study NCT03224793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm
Study NCT00449618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100 mg
Description: dose of 100 mg administered on awakening or at bedtime
Study NCT00449618 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory blood pressure monitoring
Description: Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
Study NCT00449618 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ambulatory blood pressure monitoring
Description: Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
Study NCT00449618 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chronotherapy, timing of medication
Description: Dosing on awakening versus bedtime
Study NCT00449618 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Chronotherapy, timing of medication
Description: Dosing on awakening versus bedtime
Study NCT00449618 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use of placebo on awakening versus bedtime
Study NCT00979576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 M + Pemetrexed
Description: BIBF 1120 medium dose bid+ Pemetrexed 500 mg/m\^2
Study NCT00979576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 H + Pemetrexed
Description: BIBF 1120 high dose bid+ Pemetrexed 500 mg/m\^2
Study NCT00979576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 RD + Pemetrexed
Description: confirmed dose of BIBF 1120 bid + Pemetrexed 500 mg/m\^2
Study NCT00979576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 L + Pemetrexed
Description: BIBF 1120 low dose bid+ Pemetrexed 500 mg/m\^2
Study NCT00979576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 Placebo + Pemetrexed
Description: placebo BIBF 1120 bid + Pemetrexed 500 mg/m\^2
Study NCT02535975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablets metformin 500 mg PO three times a day for 24 weeks
Study NCT02535975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets placebo PO three times a day for 24 weeks
Study NCT03942484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rPMS device
Description: Pelvic floor muscle contractions will be induced by the device.
Study NCT00703417 — intervention group
Intervention type: DEVICE
Intervention: magnetic Resonance Imaging
Description: MRI of the calcaneus, the distal tibia, the distal radius and also lower back.
Study NCT00703417 — intervention group
Intervention type: DEVICE
Intervention: Computed Tomography
Description: CT scan of the lower back and hip
Study NCT00703417 — intervention group
Intervention type: DEVICE
Intervention: High resolution peripheral quantitative computed tomography
Description: HR-pQCT of the distal radius and distal tibia
Study NCT04517097 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood sample
Description: one blood sample and one questionnaire to each patient and salaried staff included
Study NCT03602300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravidasvir test formulation produced by Doppel
Description: To compare the rate and extent of absorption for RDV when administered as a single 200 mg oral dose of the proposed commercial product (test) produced by Doppel Farmaceutici with the clinical trial product (reference) manufactured by EEPI in healthy volunteers, under fasted conditions.
Study NCT03602300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ravidasvir reference formulation produced by EEPI
Description: To compare the rate and extent of absorption for RDV when administered as a single 200 mg oral dose of the proposed commercial product (test) produced by Doppel Farmaceutici with the clinical trial product (reference) manufactured by EEPI in healthy volunteers, under fasted conditions.
Study NCT02734498 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive Treatment (ECT) Right Unilateral
Description: Intervention is electroconvulsive treatment (ECT) involves a brief electrical stimulation of the brain while the patient is under anesthesia. Performed unilateral on the right side.
Study NCT02734498 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive Treatment (ECT) - Bilateral
Description: Intervention is electroconvulsive treatment (ECT) involves a brief electrical stimulation of the brain while the patient is under anesthesia. Performed Bilateral.
Study NCT00992043 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine
Study NCT00992043 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: creatine
Study NCT00992043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Study NCT00992043 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise training
Study NCT01215487 — intervention group
Intervention type: PROCEDURE
Intervention: Stem Cell and Mutational Assay
Description: Laboratory blood testing
Study NCT02022787 — intervention group
Intervention type: OTHER
Intervention: patients with renal cell carcinoma
Description: Chemokines that may be elevated in patients with RCC
Study NCT04045964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine replacement therapy (NRT)
Description: Participants were provided with either 2 weeks of 14-mg or 21-mg transdermal nicotine patches for every smoker in the home
Study NCT04045964 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational advice
Description: Received two in-hospital motivational advice sessions by a research associate (RA). The RA adapted session content from a previous tobacco-smoke exposure protocol
Study NCT04045964 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quitline referral
Description: Quitline participants received information about tobacco-smoke exposure reduction and a referral to a tobacco Quitline.
Study NCT00248209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Wellbutrin XL
Description: Patients randomized to the bupropion treatment group will receive bupropion XL150 mg in the AM for 7 days increasing to 300mg/day (single daily dose). The investigator can increase the dose to 450mg per day at Day 28 if clinically indicated.
Study NCT01516723 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid sirolimus- and everolimus-eluting stents (ORSIRO, XIENCE PRIME)
Description: Recanalization of totally occluded coronary arteries
Study NCT01516723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid sirolimus- and everolimus-eluting stents (ORSIRO, XIENCE PRIME)
Description: Recanalization of totally occluded coronary arteries
Study NCT03718715 — intervention group
Intervention type: DRUG
Intervention: Metformin
Description: Receiving Metformin is no study intervention. The investigators have no influence on the Metformin treatment. All participants receive Metformin provided by the health care system. The individual case determine dose and frequency of the treatment as part of the usual therapy guidelines.
Study NCT01877161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive magnetic stimulation to superior temporal gyrus
Description: Repetitive magnetic stimulation to superior temporal gyrus
Study NCT01877161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive magnetic stimulation to middle temporal gyrus
Description: Repetitive magnetic stimulation to middle temporal gyrus
Study NCT01877161 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive magnetic stimulation (Sham)
Description: Repetitive magnetic stimulation (Sham)
Study NCT01886508 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve-spring radical hysterectomy
Description: Nerve-spring radical hysterectomy that is reserve some pelvic autonomic nerves during radical hysterectomy. Reserve hypogastric nerve trunk during dissecting cardinal ligament. Reserve pelvic splanchnic nerve trunk during exsecting uterosacral ligament. Reserve bladder nerve of pelvic plexus during dissecting vesicouterine ligament.
Study NCT01886508 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radical hysterectomy
Description: Radical hysterectomy is Piver III hysterectomy and Q-M classification Type C1 hysterectomy.
Study NCT02589145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Dose Escalation Phase Starting dose of Lenalidomide: 50 mg by mouth on Days -9 to -2.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Phase I.
Study NCT02589145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: 1000 mg by mouth on Days -9 to -2.
Study NCT02589145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine administered as a loading dose of 75 mg/m2 by vein on Day -8 and 2775 mg by vein on Day -3.
Study NCT02589145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan test dose administered by vein either as outpatient before admission, or as inpatient on day -10. The test dose of 32 mg/m2 based on actual body weight. Doses of days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1.